OBJECTIVE: To investigate the role of the inducible nitric oxide synthase activation-induced excess nitric oxide formation on the rate of hepatic glucose production during fully resuscitated murine septic shock. DESIGN: Prospective, controlled, randomized animal study. SETTING: University animal research laboratory. SUBJECTS: Male C57Bl/6 and B6.129P2-Nos2(tm1Lau)/J (iNOS-/-) mice. INTERVENTIONS: Fifteen hours after cecal ligation and puncture, anesthetized, mechanically ventilated and instrumented mice (wild-type controls, n = 13; iNOS-/-, n = 12; wild-type mice receiving 5 mg.kg(-1) i.p. of the selective iNOS inhibitor GW274150 immediately after cecal ligation and puncture, n =8) received continuous i.v. hydroxyethylstarch and norepinephrine to achieve normotensive and hyperdynamic hemodynamics. MEASUREMENTS AND RESULTS: Measurements were recorded 18, 21 and 24 h after cecal ligation and puncture. Liver microcirculatory perfusion and capillary hemoglobin O2 saturation (laser Doppler flowmetry and remission spectrophotometry) were well maintained in all groups. Despite significantly lower norepinephrine doses required to achieve the hemodynamic targets, the rate of hepatic glucose production (gas chromatography--mass spectrometry measurements of tissue isotope enrichment during continuous i.v. 1,2,3,4,5,6-13C6-glucose infusion) at 24 h after cecal ligation and puncture was significantly higher in both iNOS-/- and GW274150-treated mice, which was concomitant with a significantly higher hepatic phosphoenolpyruvate carboxykinase activity (spectrophotometry) in these animals. CONCLUSIONS: In normotensive, hyperdynamic septic shock, both pharmacologic and genetic deletion of the inducible nitric oxide synthase allowed maintenance of hepatic glucose production, most likely due to maintained activity of the key regulatory enzyme of gluconeogenesis, phosphoenolpyruvate carboxykinase.
OBJECTIVE: To investigate the role of the inducible nitric oxide synthase activation-induced excess nitric oxide formation on the rate of hepatic glucose production during fully resuscitated murineseptic shock. DESIGN: Prospective, controlled, randomized animal study. SETTING: University animal research laboratory. SUBJECTS: Male C57Bl/6 and B6.129P2-Nos2(tm1Lau)/J (iNOS-/-) mice. INTERVENTIONS: Fifteen hours after cecal ligation and puncture, anesthetized, mechanically ventilated and instrumented mice (wild-type controls, n = 13; iNOS-/-, n = 12; wild-type mice receiving 5 mg.kg(-1) i.p. of the selective iNOS inhibitor GW274150 immediately after cecal ligation and puncture, n =8) received continuous i.v. hydroxyethylstarch and norepinephrine to achieve normotensive and hyperdynamic hemodynamics. MEASUREMENTS AND RESULTS: Measurements were recorded 18, 21 and 24 h after cecal ligation and puncture. Liver microcirculatory perfusion and capillary hemoglobin O2 saturation (laser Doppler flowmetry and remission spectrophotometry) were well maintained in all groups. Despite significantly lower norepinephrine doses required to achieve the hemodynamic targets, the rate of hepatic glucose production (gas chromatography--mass spectrometry measurements of tissue isotope enrichment during continuous i.v. 1,2,3,4,5,6-13C6-glucose infusion) at 24 h after cecal ligation and puncture was significantly higher in both iNOS-/- and GW274150-treated mice, which was concomitant with a significantly higher hepatic phosphoenolpyruvate carboxykinase activity (spectrophotometry) in these animals. CONCLUSIONS: In normotensive, hyperdynamic septic shock, both pharmacologic and genetic deletion of the inducible nitric oxide synthase allowed maintenance of hepatic glucose production, most likely due to maintained activity of the key regulatory enzyme of gluconeogenesis, phosphoenolpyruvate carboxykinase.
Authors: Martin Siegemund; Jasper van Bommel; Lothar A Schwarte; Wolfgang Studer; Thierry Girard; Stephan Marsch; Peter Radermacher; Can Ince Journal: Intensive Care Med Date: 2005-06-15 Impact factor: 17.440
Authors: Eberhard Barth; Peter Radermacher; Christoph Thiemermann; Sandra Weber; Michael Georgieff; Gerd Albuszies Journal: Crit Care Med Date: 2006-02 Impact factor: 7.598
Authors: David Brealey; Sekhar Karyampudi; Thomas S Jacques; Marco Novelli; Ray Stidwill; Val Taylor; Ryszard T Smolenski; Mervyn Singer Journal: Am J Physiol Regul Integr Comp Physiol Date: 2003-11-06 Impact factor: 3.619
Authors: Michael Gröger; Melanie Hogg; Essam Abdelsalam; Sandra Kress; Andrea Hoffmann; Bettina Stahl; Enrico Calzia; Ulrich Wachter; Josef A Vogt; Rui Wang; Tamara Merz; Peter Radermacher; Oscar McCook Journal: Front Med (Lausanne) Date: 2022-04-29
Authors: Xizhong Cui; Virginia Besch; Alfia Khaibullina; Adrienne Hergen; Martha Quezado; Peter Eichacker; Zenaide M N Quezado Journal: Intensive Care Med Date: 2007-08-08 Impact factor: 17.440
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-04 Impact factor: 17.440
Authors: Katja Wagner; Ulrich Wachter; Josef A Vogt; Angelika Scheuerle; Oscar McCook; Sandra Weber; Michael Gröger; Bettina Stahl; Michael Georgieff; Peter Möller; Andreas Bergmann; Frauke Hein; Enrico Calzia; Peter Radermacher; Florian Wagner Journal: Intensive Care Med Exp Date: 2013-10-29
Authors: Emiel Hendrik Post; Fuhong Su; Koji Hosokawa; Fabio Silvio Taccone; Antoine Herpain; Jacques Creteur; Daniel De Backer; Jean-Louis Vincent Journal: BMC Nephrol Date: 2017-05-31 Impact factor: 2.388